Regeneron Pharmaceuticals Equity 2024

Regeneron Pharmaceuticals Aktienanalyse

What does Regeneron Pharmaceuticals do?

Regeneron Pharmaceuticals Inc. is an American biotechnology company founded in 1988 by Leonard Schleifer. The company is headquartered in Tarrytown, New York and employs approximately 8,500 people worldwide. Regeneron is known for its research in the areas of cancer therapies, eye diseases, and asthma. Regeneron operates a business model based on the research and development of biotechnological drugs. The company invests heavily in research and seeks new compounds that can fight inflammation and cancer. Regeneron develops its products using the reverse transcriptase polymerase chain reaction (RT-PCR), a method for amplifying RNA molecules into DNA. This method allows for the rapid production and analysis of large amounts of genetic material. The company is divided into several divisions, including ophthalmology, inflammatory diseases, oncology, and neurology. Regeneron also produces a wide range of biopharmaceutical products, including antibodies, interleukins, enzymes, and fusion proteins. One of Regeneron's most popular products is EYLEA (Aflibercept), a medication used to treat retinal diseases such as age-related macular degeneration. EYLEA has been on the market since 2011 and has proven to be highly effective. The medication is a blockbuster for Regeneron and accounts for a significant portion of its product revenue. Another important product from Regeneron is Dupixent (Dupilumab), a medication used to treat atopic dermatitis and severe asthma. The medication has been on the market since 2017 and has quickly established itself as a key treatment for asthma. Dupixent is produced in collaboration with Sanofi. Regeneron has also conducted promising research in the field of oncology. The company has developed a range of cancer therapies that are in the clinical phase of development. One example is the antibody Libtayo, which is used to treat squamous cell carcinomas. In its recent history, Regeneron has played a major role in the research and development of antibodies for the treatment of COVID-19. Regeneron was the first company to receive funding from the US government for the development of an antibody cocktail for the treatment of COVID-19. The medication, consisting of the antibodies Casirivimab and Imdevimab, was granted emergency use authorization by the US Food and Drug Administration in November 2020. Regeneron also has an extensive partnership with pharmaceutical company Sanofi. The two companies have jointly developed products such as Praluent (Alirocumab), a medication used to lower cholesterol levels, and Kevzara (Sarilumab), a medication used to treat rheumatoid arthritis. Overall, in recent years, Regeneron has built a strong position as a leading biotechnology company. The company has an impressive product pipeline and has developed a wide range of important medications. Regeneron continues to work on the development of new therapies and has the potential to play a significant role in the biotechnology industry in the coming years. Regeneron Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Regeneron Pharmaceuticals revenue by segment

In the annual report of the Regeneron Pharmaceuticals share (US75886F1075, 881535, REGN), it breaks down its revenues into 1 segments: 1. Medicines. The Regeneron Pharmaceuticals stock (WKN: 881535, ISIN: US75886F1075, Ticker Symbol: REGN) is a leading investment for investors interested in participating in the Health Care sector.

Equity Details

Analyzing Regeneron Pharmaceuticals's Equity

Regeneron Pharmaceuticals's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Regeneron Pharmaceuticals's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Regeneron Pharmaceuticals's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Regeneron Pharmaceuticals's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Regeneron Pharmaceuticals’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Regeneron Pharmaceuticals Stock

What is the equity of Regeneron Pharmaceuticals this year?

Regeneron Pharmaceuticals has equity of 25.97 B USD this year.

What was the equity of Regeneron Pharmaceuticals compared to the previous year?

The equity of Regeneron Pharmaceuticals has increased/decreased by 14.6% increased compared to the previous year.

What impact does a high equity have on investors of Regeneron Pharmaceuticals?

A high equity is advantageous for investors of Regeneron Pharmaceuticals as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Regeneron Pharmaceuticals?

A low equity can be a risk for investors of Regeneron Pharmaceuticals, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Regeneron Pharmaceuticals affect the company?

An increase in equity of Regeneron Pharmaceuticals can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Regeneron Pharmaceuticals affect the company?

A reduction in equity of Regeneron Pharmaceuticals can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Regeneron Pharmaceuticals?

Some factors that can affect the equity of Regeneron Pharmaceuticals include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Regeneron Pharmaceuticals so important for investors?

The equity of Regeneron Pharmaceuticals is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Regeneron Pharmaceuticals take to change the equity?

To change equity, Regeneron Pharmaceuticals can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Regeneron Pharmaceuticals pay?

Over the past 12 months, Regeneron Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Regeneron Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Regeneron Pharmaceuticals?

The current dividend yield of Regeneron Pharmaceuticals is .

When does Regeneron Pharmaceuticals pay dividends?

Regeneron Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Regeneron Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Regeneron Pharmaceuticals located?

Regeneron Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Regeneron Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Regeneron Pharmaceuticals from 4/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 4/19/2024.

When did Regeneron Pharmaceuticals pay the last dividend?

The last dividend was paid out on 4/19/2024.

What was the dividend of Regeneron Pharmaceuticals in the year 2023?

In the year 2023, Regeneron Pharmaceuticals distributed 0 USD as dividends.

In which currency does Regeneron Pharmaceuticals pay out the dividend?

The dividends of Regeneron Pharmaceuticals are distributed in USD.